$ZEPP

Zepp Health Corp

0
2
1

No SEC Form 4 filings for $ZEPP in the last 30 days.

See all $ZEPP insider activity →
Med

Zepp Health Corp (ZEPP): Financial results for Q2 2026

Zepp Health Corp (ZEPP) furnished an SEC Form 6-K — earnings release. Exhibit 99.1 Zepp Health Corporation Reports Second Quarter of 2026 Unaudited Financial Results MILPITAS, Calif., September 1, 2026 /PRNewswire/ -- Zepp Health Corporation (NYSE: ZEPP) (“Zepp”, the “Company” or “we”) today announced its unaudited financial results for the second

Zepp Health Corporation Reports Second Quarter of 2026 Unaudited Financial Results

Zepp Health (NYSE: ZEPP) reported Q2 2026 revenue of $63.5M, up 6.9% YoY. Gross margin rose to 37.4%, but net loss widened to $11.3M due to FX headwinds and R&D investments. Cash reserves grew to $106.3M. Management highlighted product mix improvements and strong demand for higher-end models. Q3 revenue is expected between $68M and $73M.

Zepp Health Corporation to Report First Quarter 2026 Financial Results on June 8, 2026

Zepp Health Corporation (NYSE: ZEPP) said it will release its unaudited first-quarter 2026 financial results on June 8, 2026. The company will host a conference call at 9:30 p.m. ET the same day, with a live webcast and an archived version on its investor site. A telephone replay will be available until June 15, 2026.

ZEPP sentiment & insider activity

Over the past 7 days, alphai's AI scored 3 news stories mentioning ZEPP (Zepp Health Corp). Coverage has skewed bearish: 0 bullish, 2 neutral, and 1 bearish.

Recent ZEPP coverage spans financial news and earnings.

What's driving ZEPP

  • Earnings show modest top‑line growth but widening loss; guidance suggests continued revenue expansion.

    SEC EDGAR 6-K · Sep 2, 2026

  • Revenue growth and margin expansion suggest improving fundamentals, but higher loss and guidance indicate modest upside.

    prnewswire.com · Sep 2, 2026

  • This is an earnings-timing update that can drive pre-earnings positioning and volatility ahead of reported Q1 2026 results.

    prnewswire.com · May 26, 2026

  • Zepp Health has narrowed its Q4 2025 EPS loss significantly compared to the previous year, indicating operational improvement. However, persistent unprofitability and a low P/S ratio suggest ongoing valuation concerns. The positive revenue trend may support short-term price stability, but fundamental challenges remain.

    Simply Wall St · Mar 16, 2026

  • Zepp Health has demonstrated strong revenue growth in Q3, with a 78.5% increase, indicating operational momentum. However, the forecasted slowdown to approximately 40% growth in the current quarter suggests potential deceleration.

    Benzinga · Nov 7, 2025

alphai scores every news story that mentions ZEPP with an AI model for sentiment and relevance, and aggregates insider trades from Zepp Health Corp's SEC EDGAR Form 4 filings. Figures refresh continuously.

News on $ZEPP

Score

Zepp Health Corp (ZEPP): Financial results for Q2 2026

Zepp Health Corp (ZEPP) furnished an SEC Form 6-K — earnings release. Exhibit 99.1 Zepp Health Corporation Reports Second Quarter of 2026 Unaudited Financial Results MILPITAS, Calif., September 1, 2026 /PRNewswire/ -- Zepp Health Corporation (NYSE: ZEPP) (“Zepp”, the “Company” or “we”) today announced its unaudited financial results for the second

Zepp Health (ZEPP) Q4 Loss Narrows To US$0.69 EPS Challenging Bearish Profitability Narratives

Zepp Health (ZEPP) reported a Q4 2025 EPS loss of US$0.69 on US$85.2 million in revenue, a significant improvement from the US$2.29 loss in Q4 2024. Despite narrowing quarterly losses and increased revenue, the company remains unprofitable with a trailing twelve-month net loss of US$40.1 million and an annualized earnings decline of 53.8% over five years. The article discusses both bullish arguments, focused on product innovation and premium segment expansion, and bearish concerns about persistent unprofitability and a P/S ratio of 0.9x compared to the industry average of 2.4x.

Related tickers